New targets for NAFLDKey points
Summary: Non-alcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver disease worldwide. It is characterised by steatosis, liver inflammation, hepatocellular injury and progressive fibrosis. Several preclinical models (dietary and genetic animal models) of NAFLD have deepened our un...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-12-01
|
| Series: | JHEP Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589555921001221 |
| id |
doaj-9d4fca391fdc4664876e3b618ff56737 |
|---|---|
| record_format |
Article |
| spelling |
doaj-9d4fca391fdc4664876e3b618ff567372021-10-11T04:16:43ZengElsevierJHEP Reports2589-55592021-12-0136100346New targets for NAFLDKey pointsLucia Parlati0Marion Régnier1Hervé Guillou2Catherine Postic3Université de Paris, Institut Cochin, CNRS, INSERM, F- 75014 Paris, France; Hôpital Cochin, 24, rue du Faubourg Saint Jacques, 75014 Paris, FranceUCLouvain, Université catholique de Louvain, Walloon Excellence in Life Sciences and BIOtechnology, Louvain Drug Research Institute, Metabolism and Nutrition Research Group, Brussels, BelgiumToxalim, Université de Toulouse, INRA, ENVT, INP-Purpan, UPS, Toulouse 31027, FranceUniversité de Paris, Institut Cochin, CNRS, INSERM, F- 75014 Paris, France; Corresponding author. Address: Institut Cochin - 24 rue du Faubourg Saint-Jacques, France.Summary: Non-alcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver disease worldwide. It is characterised by steatosis, liver inflammation, hepatocellular injury and progressive fibrosis. Several preclinical models (dietary and genetic animal models) of NAFLD have deepened our understanding of its aetiology and pathophysiology. Despite the progress made, there are currently no effective treatments for NAFLD. In this review, we will provide an update on the known molecular pathways involved in the pathophysiology of NAFLD and on ongoing studies of new therapeutic targets.http://www.sciencedirect.com/science/article/pii/S2589555921001221NAFLDNASHSREBP-1cChREBPFXRLXR |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Lucia Parlati Marion Régnier Hervé Guillou Catherine Postic |
| spellingShingle |
Lucia Parlati Marion Régnier Hervé Guillou Catherine Postic New targets for NAFLDKey points JHEP Reports NAFLD NASH SREBP-1c ChREBP FXR LXR |
| author_facet |
Lucia Parlati Marion Régnier Hervé Guillou Catherine Postic |
| author_sort |
Lucia Parlati |
| title |
New targets for NAFLDKey points |
| title_short |
New targets for NAFLDKey points |
| title_full |
New targets for NAFLDKey points |
| title_fullStr |
New targets for NAFLDKey points |
| title_full_unstemmed |
New targets for NAFLDKey points |
| title_sort |
new targets for nafldkey points |
| publisher |
Elsevier |
| series |
JHEP Reports |
| issn |
2589-5559 |
| publishDate |
2021-12-01 |
| description |
Summary: Non-alcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver disease worldwide. It is characterised by steatosis, liver inflammation, hepatocellular injury and progressive fibrosis. Several preclinical models (dietary and genetic animal models) of NAFLD have deepened our understanding of its aetiology and pathophysiology. Despite the progress made, there are currently no effective treatments for NAFLD. In this review, we will provide an update on the known molecular pathways involved in the pathophysiology of NAFLD and on ongoing studies of new therapeutic targets. |
| topic |
NAFLD NASH SREBP-1c ChREBP FXR LXR |
| url |
http://www.sciencedirect.com/science/article/pii/S2589555921001221 |
| work_keys_str_mv |
AT luciaparlati newtargetsfornafldkeypoints AT marionregnier newtargetsfornafldkeypoints AT herveguillou newtargetsfornafldkeypoints AT catherinepostic newtargetsfornafldkeypoints |
| _version_ |
1716828744753086464 |